| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96547e853272614b80b1cabdf8528041 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2446-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6837
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6837
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad9acc1de2b9c4fb3849a576c82f4796
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2a2e85bada9dee07810bfa839f568ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a522941fdc1ae8acaf1ddc2ecf0c443 |
| publicationDate |
2022-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113970639-A |
| titleOfInvention |
A marker for predicting the sensitivity of patients with chronic myeloid leukemia to tyrosine kinase inhibitors and its application |
| abstract |
The invention discloses a marker for predicting the sensitivity of patients with chronic myeloid leukemia to tyrosine kinase inhibitors and its application. The marker includes CTSS, CXCL3 and/or RAB27B. By detecting the expression levels of markers, it is possible to determine whether patients with chronic myeloid leukemia are resistant to tyrosine kinase inhibitors, so as to facilitate targeted treatment, and has a good clinical application prospect. |
| priorityDate |
2021-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |